ArticleJNCI cancer spectrum2025

The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials.

Elaine Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.